Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical Lesions
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
single arm phase II trial evaluating Pembrolizumab single agent as neoadjuvant treatment
before surgical conization and/or partial or radical vulvectomy in patients with
pre-neoplastic cervical and vulvar high grade lesions.